HC Wainwright Forecasts Ocugen’s Q1 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ocugen in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.07) for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS and Q4 2027 earnings at ($0.03) EPS.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The firm had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.42 million.

Other analysts also recently issued research reports about the company. Wall Street Zen downgraded Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a research note on Wednesday, March 25th. Canaccord Genuity Group initiated coverage on Ocugen in a research note on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Oppenheimer initiated coverage on Ocugen in a report on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.75.

Ocugen Stock Performance

NASDAQ:OCGN opened at $1.48 on Tuesday. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06. Ocugen has a 1 year low of $0.64 and a 1 year high of $2.73. The stock’s 50 day simple moving average is $1.86 and its two-hundred day simple moving average is $1.58. The company has a market cap of $501.01 million, a price-to-earnings ratio of -6.17 and a beta of 2.30.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. SmartHarvest Portfolios LLC acquired a new position in Ocugen during the 4th quarter valued at about $31,000. BNP Paribas Financial Markets increased its position in Ocugen by 56.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after buying an additional 13,326 shares in the last quarter. NewEdge Advisors LLC increased its position in Ocugen by 198.0% during the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after buying an additional 24,460 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Ocugen during the 4th quarter valued at about $38,000. Finally, Cora Capital Advisors LLC increased its position in Ocugen by 27.5% during the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after buying an additional 6,500 shares in the last quarter. 10.27% of the stock is owned by institutional investors and hedge funds.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.